On September 8, 2022 MAIA Biotechnology, Inc., (NYSE American: MAIA) ("MAIA", the "Company"), a targeted therapy, immuno-oncology company focused on developing potential first-in-class oncology drugs, reported that the management team will participate in the H.C. Wainwright 24th Annual Global Investment Conference that will be held September 12th – 14th (Press release, MAIA Biotechnology, SEP 8, 2022, View Source [SID1234619278]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The MAIA team is scheduled to present on September 12th at 7:00 am ET and will host investor meetings at the Conference through September 14th.

A webcast of the presentation will be available on the News & Events page of the Investors section of the Company’s website. A replay of the webcast will be available for 30 days following the event.